Elanco Animal Health Incorporated
NYSE:ELANDrug Manufacturers - Specialty & Generic
-$0.84 today
- Market cap
- $13.35B
- Beta
- 1.70
- P/E (TTM)
- -48.1
- EPS (TTM)
- -$0.49
Volume 5.78M
Average 6.04M
ELAN Revenue
Total income from selling goods and services before any costs are deducted; the top line of the income statement.
Elanco Animal Health IncorporatedNYSE: ELAN
Revenue · Q3 FY2026 · quarter ended Sep 2026
Revenue grows in line with its trailing trend
Q3 FY2026 revenue of $1.27B rose 11.3% year over year, behind the +12.1% change in trailing-twelve-month revenue. Sequentially, it fell 7.5% from the prior quarter. Over 3 fiscal years it compounded at +2.2% a year.
Context
- Revenue increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether revenue reaches the consensus estimate from 9 analysts of $5.18B (+10.0%) for the fiscal year ending Dec 2026, a step up from the +6.2% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- $1.27B-7.5% QoQ
- Last fiscal yearDec 2025
- $4.72B+6.2% YoY
- LTMSep 2026
- $5.15B+12.1% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +11.3% | +4.8% | -6.4 pp |
| 1 year | +6.2% | +10.0% | +3.7 pp |
| 3-year CAGR | +2.2% | +6.6% | +4.4 pp |
| 5-year CAGR | +5.5% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Revenue history
USD · from the income statement
- Latest · FY2025
- 4.72B USD
- Year-over-year change
- +6.2%
- 4-year CAGR
- -0.3%
| Period | Period end | Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 4.72B | +6.2% |
| FY2024 | 2024-12-31 | 4.44B | +0.5% |
| FY2023 | 2023-12-31 | 4.42B | +0.1% |
| FY2022 | 2022-12-31 | 4.41B | -7.4% |
| FY2021 | 2021-12-31 | 4.76B | — |
Revenue vs competitors
How ELAN compares with its peers on the latest reported figures
- ELAN's LTM Sep 2026 revenue of $5.15B is the 3rd highest of the 6 companies compared; the peer median is $4.66B.
- Its year-over-year change of +12.1% is the 2nd highest of 6, against a peer median of +4.2%.
- Over three fiscal years its annual growth of +2.2% compares with a peer median of +5.4%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Jun 2026 | $66.4B | +4.2% | +3.1% | |
| LTM Jun 2026 | $9.52B | +1.4% | +5.4% | |
| LTM Sep 2026 | $5.15B | +12.1% | +2.2% | |
| LTM Sep 2026 | $4.66B | +11.9% | +8.5% | |
| LTM Mar 2026 | $1.5B | +26.0% | +11.2% | |
| LTM Aug 2026 | $883.99M | -0.3% | +1.9% | |
| Peer median (excluding ELAN) | $4.66B | +4.2% | +5.4% | |
Competitors are the stored peer set for ELAN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 4.76B | 4.41B | 4.42B | 4.44B | 4.72B |
| Cost of Revenue | 2.69B | 2.44B | 2.48B | 2.53B | 2.67B |
| Gross Profit | 2.08B | 1.97B | 1.94B | 1.91B | 2.05B |
| Gross Margin | 43.6% | 44.7% | 43.9% | 43.0% | 43.5% |
| Research & Development | 369M | 321M | 327M | 344M | 368M |
| Selling, General & Admin | 1.4B | 1.27B | 1.29B | 1.31B | 1.43B |
| Operating Expenses | 1.77B | 1.59B | 1.61B | 1.66B | 1.8B |
| Depreciation & Amortization | 716M | 682M | 694M | 662M | 680M |
| EBITDA | 409M | 866M | (224M) | 1.49B | 676M |
| EBITDA Margin | 8.6% | 19.6% | -5.1% | 33.5% | 14.3% |
| Operating Income | 304M | 384M | 326M | 251M | 252M |
| Operating Margin | 6.4% | 8.7% | 7.4% | 5.7% | 5.3% |
| Interest Income | 0 | 0 | 0 | 0 | 45M |
| Interest Expense | 264M | 256M | 277M | 339M | 220M |
| Other Income / Expenses | (875M) | (456M) | (1.52B) | 237M | (476M) |
| Income Before Tax | (571M) | (72M) | (1.2B) | 488M | (224M) |
| Pre-Tax Margin | -12.0% | -1.6% | -27.1% | 11.0% | -4.8% |
| Income Tax Expense | (88M) | 6M | 36M | 150M | 8M |
| Net Income | (483M) | (78M) | (1.23B) | 338M | (232M) |
| Net Margin | -10.1% | -1.8% | -27.9% | 7.6% | -4.9% |
| EPS (Basic) | (0.97) | (0.15) | (2.50) | 0.68 | (0.47) |
| EPS (Diluted) | (0.97) | (0.15) | (2.50) | 0.68 | (0.47) |
| Weighted Avg Shares | 487.2M | 488.3M | 492.3M | 494M | 496.4M |
| Weighted Avg Shares (Diluted) | 487.2M | 488.3M | 492.3M | 497.3M | 496.4M |
Elanco Animal Health Incorporated
NYSE:ELAN
Intrinsic Alpha fair value
Locked
Current Price
$26.70
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.